Cargando…
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
Myasthenia gravis (MG) is a rare autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. MG is classified by the antigen specificity of these antibodies. Acetylcholine receptor (AChR) antibodies are the most common type (74–88%), followed by anti-muscle specific kinase (...
Autores principales: | Waheed, Waqar, Newman, Eric, Aboukhatwa, Marwa, Moin, Maryam, Tandan, Rup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288180/ https://www.ncbi.nlm.nih.gov/pubmed/35855752 http://dx.doi.org/10.2147/TCRM.S266031 |
Ejemplares similares
-
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Publicado: (2022) -
Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020) -
Thymectomy in myasthenia gravis: “The real world” experience beyond studies
por: Waheed, Waqar, et al.
Publicado: (2022) -
Subxiphoid completion thymectomy for refractory non-thymomatous myasthenia gravis
por: Ambrogi, Vincenzo, et al.
Publicado: (2020) -
Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)